Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark
Eugène Brailovski(Kettering University), Heather Landau(Memorial Sloan Kettering Cancer Center), Xia Wu(China Medical University), Raymond L. Comenzo(Tufts Medical Center), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute), Víctor H. Jiménez‐Zepeda(University of Calgary), Christopher Wanjiku(University of North Carolina at Chapel Hill), Grace Gallagher(Kettering University), Mithat Gönen(Memorial Sloan Kettering Cancer Center), Sascha A. Tuchman(University of North Carolina at Chapel Hill), Andrew Staron(Boston University), Abhishek Janardan(Boston University), Alfred Chung(University of California, San Francisco), Amelia Piteo(The Barbara Ann Karmanos Cancer Institute), Vaishali Sanchorawala(Boston Medical Center)
Cited by 0
Related Papers
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k